Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Solute carrier family 26 member 9 (SLC26A9) and cystic fibrosis transmembrane conductance regulator (CFTR) disruptors as novel therapeutics for cystic fibrosis.
EF 2015-16
Résumé
Epithelial ion channels and transporters maintain pulmonary homeostasis and a loss-of-function mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) anion channel reduce airway secretion and cause the disease cystic fibrosis (CF). The most common CF mutation, deletion of phenylalanine at position 508 (F508del-CFTR), results in misfolding and retention of the mutant in the endoplasmic reticulum (ER), leading to a lack of the surface expression of CFTR. Although small molecule correctors are presently in development, the most effective one so far (VX-809) only partially rescues CFTR folding and provides very modest clinical benefit. Another conductive anion pathway, SLC26A9, has been proposed as an alternative therapeutic target for respiratory diseases because 1) SLC26A9 is activated by inflammation and prevents airway obstruction in mice, 2) polymorphisms that reduce SLC26A9 expression are associated with asthma in humans, 3) the SLC26A9 gene was identified as a modifier of human CF severity. However, the cytosolic Regulatory (R) domain of CFTR interacts with the Sulfate Transporter and Anti-Sigma factor antagonist (STAS) domain of SLC26A9 leading to the retention of both ion channels in the ER. Disrupting the interaction between SLC26A9 and the immature F508del-CFTR would relieve inhibition by the R domain and may allow SLC26A9 trafficking to the plasma membrane, enabling it to act as an alternative ion channel that bypasses CFTR. The goal of this project is therefore to study the interaction between SLC26A9 and CFTR, identify molecules that disrupt it, investigate their mechanisms of action, and demonstrate pharmacological activation of chloride secretion in CF airway epithelial cells.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
350174
Name
Sato Yukiko
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Solute carrier family 26 member 9 (SLC26A9) and cystic fibrosis transmembrane conductance regulator (CFTR) disruptors as novel therapeutics for cystic fibrosis.
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cftr; Chronic Obstructive Pulmonary Disease; Cystic Fibrosis; High-Throughput Drug Screen; Ion Channel Activator; Lung Disease; Protein Trafficking; Protein-Protein Disruptor; Protein-Protein Interaction; Slc26a9
Abstract
Epithelial ion channels and transporters maintain pulmonary homeostasis and a loss-of-function mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) anion channel reduce airway secretion and cause the disease cystic fibrosis (CF). The most common CF mutation, deletion of phenylalanine at position 508 (F508del-CFTR), results in misfolding and retention of the mutant in the endoplasmic reticulum (ER), leading to a lack of the surface expression of CFTR. Although small molecule correctors are presently in development, the most effective one so far (VX-809) only partially rescues CFTR folding and provides very modest clinical benefit. Another conductive anion pathway, SLC26A9, has been proposed as an alternative therapeutic target for respiratory diseases because 1) SLC26A9 is activated by inflammation and prevents airway obstruction in mice, 2) polymorphisms that reduce SLC26A9 expression are associated with asthma in humans, 3) the SLC26A9 gene was identified as a modifier of human CF severity. However, the cytosolic Regulatory (R) domain of CFTR interacts with the Sulfate Transporter and Anti-Sigma factor antagonist (STAS) domain of SLC26A9 leading to the retention of both ion channels in the ER. Disrupting the interaction between SLC26A9 and the immature F508del-CFTR would relieve inhibition by the R domain and may allow SLC26A9 trafficking to the plasma membrane, enabling it to act as an alternative ion channel that bypasses CFTR. The goal of this project is therefore to study the interaction between SLC26A9 and CFTR, identify molecules that disrupt it, investigate their mechanisms of action, and demonstrate pharmacological activation of chloride secretion in CF airway epithelial cells.
Competitiondate
201512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Sato, Yukiko
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~